Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
Source: SeekingAlpha
2026-02-11 11:03:22 ET
Incyte ( INCY ) delivered Q4 earnings results yesterday that were mixed, with non-GAAP EPS coming in short of expectations even as revenue exceeded them. However, the number that moved the market was 2026 guidance. Management guided to a mid-point of $4.85 billion in 2026 sales, a figure that was immediately interpreted by investors as a substantial miss against the consensus expectation of $5.53 billion....
Read the full article on Seeking Alpha
For further details see:
Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
Incyte Corporation
NASDAQ: INCY
INCY Trading
-2.09% G/L:
$95.15 Last:
199,127 Volume:
$96.23 Open:
INCY Latest News
INCY Stock Data
$19,951,294,692
161,377,262
0.07%
384
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
